Paramus, United States
Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company founded in 2016. With a focus on rare and refractory epilepsy, the company is dedicated to developing drugs that target Dravet syndrome (DS) and other genetic epilepsies. Their slogan "We develop precision medicines for rare and refractory epilepsy" underlines their commitment to addressing unmet medical needs in the field.
Operating at the intersection of Biopharma, Biotechnology, Health Care, and Pharmaceutical industries, Epygenix Therapeutics is based in the United States.
Although specific details about the last investment round and the investors involved are not available at this time, Epygenix Therapeutics' targeted approach to addressing rare and genetic epilepsies positions them as a company to watch in the biopharmaceutical sector.
